you're right, threes: safety of Bavituximab in humans appears to be well-established. Actually, when I look back over the years of following Bavituximab's progress the most outstanding aspect of it is the elegance and thoroughness of the preclinical trials and the theoretical rationale upon which it is all based. Hats off to Dr Thorpe and his coworkers at the department of pharmacology at UTSW who have produced truly Nobel-quality work. Antiphospholipid monoclonal antibody therapy appears to have a bright future...mindboggling in its potential.
News 
Market Data 
Discover 
AI
